TrialThe oncologist2021

Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).

Naohiro Okano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.